Christopher Peetz sold $2.0M of MIRM
CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals, Inc.. 20,000 shares at an average of $98.92, traded Aug 10, 2026, filed Aug 11, 2026.
Score components
- +25RoleCEO
- +25Trade size$2.0M at market
- 0Share of holdings soldSold 9.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001614740-26-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $2.94 | $59k | 214,309 | Aug 11, 2026 |
| Aug 10, 2026 | SOpen-market sale Common Stock10b5-1 | -11,683 | $98.51 | $1.2M | 202,626 | Aug 11, 2026 |
| Aug 10, 2026 | SOpen-market sale Common Stock10b5-1 | -6,017 | $99.25 | $597k | 196,609 | Aug 11, 2026 |
| Aug 10, 2026 | SOpen-market sale Common Stock10b5-1 | -2,300 | $100.14 | $230k | 194,309 | Aug 11, 2026 |
| Aug 10, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 88,487 | Aug 11, 2026 |
Related signals
Other insiders at Mirum Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $978k 9,943 shares | -18% | |
| 38Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $66k 658 shares | -52% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.0M 30,000 shares | -13% | |
| 60Notable | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $4.0M 40,000 shares | -97% | |
| 41Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $600k 6,001 shares | -14% | |
| 42Moderate | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $194k 1,840 shares | -59% | |
| 42Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $611k 5,000 shares | -11% | |
| 30Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $2.4M 20,000 shares | -9% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $327k 2,721 shares | -47% | |
| 26Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $264k 2,594 shares | -31% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.